ClinicalTrials.gg
Active, not recruitingNCT04536870STAREE-HEARTUpdated Apr 2, 2025

Statins in Reducing Events in the Elderly (STAREE) Heart Sub-study

An interventional study of Echocardiography and ECG screening in Heart Failure, Atrial Fibrillation and Healthy Ageing, sponsored by Monash University. Active, not recruiting at 2 sites in Australia. Open to participants aged 70 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-02.

Sponsored by Monash University · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Dec 2019, registered Aug 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
369
Allocation
Randomized
Ages
70 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 167 studies in Heart Failure with a site in Australia — 25 open to participants now, 41 under way, 9 of them phase 3. Heart Failure · Australia.

Enrollment
67th of 135
369 · median 350
Started
2019
with 3 others
No phase
57 of 167
14 open now
Primary completion
2026-12
later than 18 of 40 live
Registered
122nd of 167
by date
Lead sponsor
6 of 167
Monash University

Among the 167 studies in Heart Failure with a site in Australia, this one is the 67th largest by enrollment of the 135 interventional ones that give a count, is one of 4 that started in 2019, is one of 57 with no phase, reaches primary completion later than 18 of the 40 other live ones, and was the 122nd registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

25 of the 167 studies in Heart Failure with a site in Australia are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 70 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 167 studies in Heart Failure with a site in Australia, or all of them as a file.
02

Study summary

The STAREE-HEART sub-study will examine the effect of statin treatment over a 3-year period compared with placebo on markers of cardiac ageing (myocardial dysfunction). This will include determining global longitudinal strain with transthoracic echocardiography, atrial fibrillation with home measures twice daily for two weeks and changes in biomarkers.

Read the detailed description

STAREE-HEART is an ancillary study nested in the Statins in Reducing Events in the Elderly (STAREE) double-blind randomised placebo-controlled trial. STAREE is investigating whether statins can prolong good health and maintain independence amongst older people and is enrolling men and women 70 years of age and over who are free from cardiovascular disease, diabetes and dementia. STAREE-HEART will recruit a subset of STAREE participants before they are randomised to STAREE study drug. STAREE-HEART will involve an additional suite of cardiac assessments in these participants and will provide detailed information about the clinical effect of statins on myocardial function.

03

Conditions studied

  • Heart Failure
  • Atrial Fibrillation
  • Healthy Ageing
  • Hypercholesterolemia
  • Myocardial Dysfunction

Keywords

  • Statin
  • Atorvastatin
  • STAREE
  • Echocardiography
  • Atrial fibrillation screening
  • Global longitudinal strain
  • Single time point screening
  • Elderly
04

Who can participate

Ages eligible
70 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women aged ≥70 years living independently in the community who are participants in the STAREE RCT and eligible for randomisation to study medication.
  • Willing and able to provide and accept the STAREE-HEART study requirements, including attendance for an echocardiogram and undertaking home monitoring via .

Exclusion criteria

Exclusion Criteria:

  • Known atrial fibrillation or atrial flutter.
  • Participants who do not wish to be informed of an abnormality under any circumstances, regardless of severity, will not be enrolled in the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
369 participants (actual)

Study arms

  • Experimental
    STAREE Statin group

    Participants in STAREE trial randomised to statin

    Diagnostic Test: Echocardiography · Diagnostic Test: ECG screening

  • Experimental
    STAREE Placebo group

    Participants in STAREE trial randomised to placebo

    Diagnostic Test: Echocardiography · Diagnostic Test: ECG screening

Interventions

  • Diagnostic testEchocardiography

    Ultrasound of heart

    Also known as: Global longitudinal strain

  • Diagnostic testECG screening

    Single lead ECG screening twice daily for two weeks

    Also known as: Alivecor

  • Diagnostic testECG Screening

    12-lead ECG screening

    Also known as: 12-lead ECG

06

What researchers measure

Primary outcomes

  1. Global longitudinal strain (GLS) measured via transthoracic echocardiography.

    Change in global longitudinal strain.

    Time frame: 3 years

Secondary outcomes

  1. Atrial fibrillation (AF) measured via single lead handheld ECG recordings.

    Development of new AF.

    Time frame: 3 years

  2. Wavelet analysis via 12-lead ECG with Energy Waveform displays.

    Increases detection of Heart Failure (HF).

    Time frame: 3 years

Other outcomes

  1. Atrial strain

    On echocardiography

    Time frame: Baseline to 3 year

  2. N- Terminal-pro-Brain Natriuretic Peptide (NT pro BNP)

    Predictor of heart failure

    Time frame: Baseline to 3 year

  3. Vascular Endothelial Growth Factor (VEG-F)

    Endothelial marker

    Time frame: Baseline to 3 year

  4. Intercellular Adhesion Molecule 1 (ICAM-1)

    Endothelial marker

    Time frame: Baseline to 3 year

  5. C-reactive protein

    Inflammatory biomarker

    Time frame: Baseline to 3 year

  6. Interleukin-6

    Inflammatory biomarker

    Time frame: Baseline to 3 year

  7. Tumour Necrosis Factor alpha (TNF alpha)

    Inflammatory biomarker

    Time frame: Baseline to 3 year

  8. Matrix metalloproteinase-9 (MMP-9)

    Fibrosis marker

    Time frame: Baseline to 3 year

  9. Tumour-derived protein tissue inhibitor of metalloproteinases-1 (TIMP-1)

    Fibrosis marker

    Time frame: Baseline to 3 year

  10. C-telopeptide of type I collagen (CTX I)

    Fibrosis marker

    Time frame: Baseline to 3 year

  11. Procollagen III N-terminal propeptide (PIIINP).

    Fibrosis marker

    Time frame: Baseline to 3 year

07

Study locations

2 sites
  • Monash University; School of Public Health and Preventative Medicine: STAREE trial
    Melbourne, Victoria 3004, Australia
  • Curtin University
    Perth, Western Australia, Australia
08

References and documents

Individual participant data

Plan to share: No — On completion of the trial, and after publication of the primary and secondary outcomes of the study, requests for access to de-identified data (to be provided through a secure online environment) may be submitted to the researchers located at the School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2019 (actual). Primary completion is estimated for Dec 2026, 84 months after the start.

Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 84 months is above that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2020
First posted
Sep 3, 2020
StartActual
Dec 12, 2019
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Apr 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04536870
Lead sponsor
Monash University
Collaborators
National Health and Medical Research Council, Australia, Curtin University
Responsible party
Ingrid Hopper (Principal Investigator, Monash University) — Principal investigator
First posted
Sep 3, 2020
Start date
Dec 12, 2019
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Apr 2, 2025

Study contacts

Ingrid Hopper
principal investigator · Monash University
Sophia Zoungas, MBBS PhD FRACP
study chair · Monash University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion